Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangsu Lianhuan Pharmaceutical Co Debt-to-EBITDA?
Jiangsu Lianhuan Pharmaceutical CoSHSE:600513 61 Debt-to-EBITDA is 19.72 as of Jun. 2026, which is 695% above its 10-year median of 2.48. GuruFocus rates SHSE:600513 with a GF Score™ of 61/100 and a GF Value™ of ¥15.63 (Fairly Valued). The stock has 9 warning signs investors should review. Among 678 Drug Manufacturers companies, Jiangsu Lianhuan Pharmaceutical Co ranks worse than 147492.48% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHSE:600513'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -74.7 Med: 2.48 Max: 36.01
Current: -74.7
During the past 13 years, the highest Debt-to-EBITDA Ratio of Jiangsu Lianhuan Pharmaceutical Co was 36.01. The lowest was -74.70. And the median was 2.48.
SHSE:600513's Debt-to-EBITDA is ranked worse than 100% of 678
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs SHSE:600513: -74.70
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Jiangsu Lianhuan Pharmaceutical Co Debt-to-EBITDA Related Terms
Jiangsu Lianhuan Pharmaceutical Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Lianhuan Pharmaceutical Co Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Lianhuan Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Lianhuan Pharmaceutical Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Lianhuan Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jiangsu Lianhuan Pharmaceutical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Debt-to-EBITDA of 19.72 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Jiangsu Lianhuan Pharmaceutical Co. This is 695% above median its historical median of 2.48. According to the industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #999999 out of 678 companies in the Drug Manufacturers industry.
Is Jiangsu Lianhuan Pharmaceutical Co's Debt-to-EBITDA too high?
Jiangsu Lianhuan Pharmaceutical Co's current Debt-to-EBITDA of 19.72 is 695% above median its 10-year median of 2.48. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Jiangsu Lianhuan Pharmaceutical Co's value of 19.72 is 1102.4% above this industry median. Based on the distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #999999 out of 678 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #999999 out of 678 companies for Debt-to-EBITDA. This places Jiangsu Lianhuan Pharmaceutical Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Jiangsu Lianhuan Pharmaceutical Co's value of 19.72 is 1102.4% above this benchmark. While the company's 10-year median is 2.48 vs. the industry median of 1.64, Jiangsu Lianhuan Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Lianhuan Pharmaceutical Co's current Debt-to-EBITDA of 19.72 is 1102.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Jiangsu Lianhuan Pharmaceutical Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Lianhuan Pharmaceutical Co's current Debt-to-EBITDA is 19.72, which is 695% above median its own 10-year median of 2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.63, compared to a current price of ¥14.88 — trading 4.8% below its estimated fair value. The current Debt-to-EBITDA is 19.72, which is 695% above median its 10-year median of 2.48 and 1102.4% above the Drug Manufacturers industry median of 1.64. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Debt-to-EBITDA is 19.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥14.88 is trading 4.8% below its estimated GF Value™ of ¥15.63.
GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600513:
Debt-to-EBITDA: 19.72 (695% above median its 10-year median of 2.48)
GF Value™: ¥15.63 vs. price of ¥14.88 (4.8% below fair value)
Industry Position: 1102.4% above the Drug Manufacturers median (#999999 of 678)
No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
61GF Score
Get the complete analysis for SHSE:600513
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600513 has been successfully added to your 
